A 33-year-old man who had been diagnosed with ALL and treated with 2 chemotherapy in childhood was diagnosed with lung adenocarcinoma.
INTRODUCTION
The survival rate of patients with childhood cancer has increased from 1970 to the present, with 5-year survival rates now approaching 80% (1).
Coincident with this improved survival has been the recognition that survivors are at risk for subsequent malignancies (2-6). It has been widely accepted that the anti-cancer drugs used in childhood damage the genomic DNA of some hematopoietic progenitors, resulting in secondary hematological malignancies (7) . Indeed, recurrent chromosome translocations were found in many cases of such malignancies (7, 8) . On the other hand, no chromosomal translocations have been reported in secondary epithelial malignancies.
Chromosomal rearrangement of the echinoderm microtubule-associated protein-like 4 gene (EML4) and of the anaplastic lymphoma kinase gene (ALK) leads to an oncogenic fusion gene that was first reported in lung adenocarcinoma (9) . This translocation may occur in less than 5% of non-small cell lung cancers (NSCLCs) and has come to be recognized as a new target of chemotherapy (9) . To the best of our knowledge, this is the first report of a case of an EML4-ALK-positive lung adenocarcinoma that 4 occurred almost 20 years after treatment for acute lymphoblastic leukemia (ALL).
CASE REPORT
A 33-year-old man who had never smoked was referred to our institution for further examination of a massive right pleural effusion on chest X-ray.
Thoracentesis was performed, and pleural fluid cytology was positive for adenocarcinoma. A computed tomography (CT) scan of his chest after the thoracentesis revealed a nodule in the right upper lobe approximately 3 cm in diameter (Fig. 1) , and stage IV NSCLC was diagnosed. When the patient was 11 years old, he had been diagnosed with ALL and enrolled in a clinical trial for juvenile high-risk ALL (10) . He had been treated with the AL851 regimen, receiving vincristine, prednisolone, daunorubicin, l-asparaginase, methotrexate, 6-mercaptopurine, doxorubicin, cytosine arabinoside, 6-mercaptopurine, and cyclophosphamide. Cranial irradiation was used to prevent central nervous system leukemia; however, thoracic irradiation was not performed (10) . Complete remission was achieved.
Considering his medical history, he was found to have a secondary lung we concluded that his lung adenocarcinoma was a secondary malignant neoplasm. In the CCSS report, the most frequent secondary epithelial malignancies occurring ≥5 years after childhood cancer were breast and thyroid cancer. However, bronchial and lung cancers were also epithelial 7 malignancies whose subsequent risks were elevated. The 30-year cumulative incidence for selected subsequent cancers was 0.1% for lung cancer, and the standardized incidence ratio (SIR) of second bronchial and lung cancers was 
